Nektar Therapeutics (NASDAQ:NKTR)‘s stock had its “buy” rating reissued by research analysts at Jefferies Group LLC in a research note issued to investors on Friday. They presently have a $23.00 price objective on the biopharmaceutical company’s stock. Jefferies Group LLC’s price objective would indicate a potential upside of 3.74% from the company’s previous close.

Several other equities research analysts have also recently commented on the stock. Zacks Investment Research raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 27th. Aegis reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Nektar Therapeutics in a research report on Wednesday, May 10th. Roth Capital set a $31.00 price objective on shares of Nektar Therapeutics and gave the company a “buy” rating in a research report on Thursday, May 11th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $29.00 price objective on shares of Nektar Therapeutics in a research report on Tuesday, April 11th. Finally, ValuEngine raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Nektar Therapeutics presently has an average rating of “Buy” and an average target price of $26.29.

Nektar Therapeutics (NKTR) traded up 1.31% during trading on Friday, hitting $22.46. 803,282 shares of the stock were exchanged. Nektar Therapeutics has a 12-month low of $11.41 and a 12-month high of $24.88. The stock has a 50 day moving average price of $19.64 and a 200-day moving average price of $17.47. The firm’s market capitalization is $3.48 billion.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.02. The company had revenue of $24.73 million during the quarter, compared to the consensus estimate of $29.43 million. Nektar Therapeutics had a negative net margin of 150.74% and a negative return on equity of 3,072.86%. The company’s revenue was down 58.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.14) earnings per share. On average, equities research analysts anticipate that Nektar Therapeutics will post ($1.17) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/07/21/nektar-therapeutics-nasdaqnktr-earns-buy-rating-from-jefferies-group-llc.html.

In other Nektar Therapeutics news, CFO Gil M. Labrucherie sold 3,179 shares of Nektar Therapeutics stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $19.55, for a total value of $62,149.45. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Robert Chess sold 5,000 shares of Nektar Therapeutics stock in a transaction on Monday, May 15th. The shares were sold at an average price of $19.79, for a total transaction of $98,950.00. Following the completion of the sale, the director now owns 276,623 shares in the company, valued at $5,474,369.17. The disclosure for this sale can be found here. Insiders sold a total of 159,803 shares of company stock worth $3,328,247 over the last quarter. Company insiders own 6.10% of the company’s stock.

Large investors have recently modified their holdings of the stock. Russell Investments Group Ltd. purchased a new position in Nektar Therapeutics during the fourth quarter valued at $979,000. GSA Capital Partners LLP purchased a new position in Nektar Therapeutics during the fourth quarter valued at $308,000. Metropolitan Life Insurance Co. NY raised its position in Nektar Therapeutics by 9.7% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 101,124 shares of the biopharmaceutical company’s stock valued at $1,241,000 after buying an additional 8,935 shares in the last quarter. Thrivent Financial for Lutherans raised its position in Nektar Therapeutics by 16.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 82,150 shares of the biopharmaceutical company’s stock valued at $1,008,000 after buying an additional 11,770 shares in the last quarter. Finally, Norges Bank purchased a new position in Nektar Therapeutics during the fourth quarter valued at $31,574,000. Hedge funds and other institutional investors own 93.85% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.